Quantcast

Industry news that matters to you.  Learn more

DHMRI and Metabolon Announce Strategic Partnership to Provide Expanded Metabolomics Capabilities

The David H. Murdock Research Institute (DHMRI) at the North Carolina Research Campus and Metabolon, Inc., recently announced that they have entered into a strategic agreement to align metabolomics research services. Metabolon is a pioneering leader in discovery metabolomics and specializes in rapidly assessing metabolism in biological samples to quickly identify prospective biomarkers and to understand metabolic effects of treatments, interventions, nutritionals, etc. The agreement complements DHMRI’s mass spectrometry and NMR‐based metabolomics services through access to Metabolon’s industry‐leading high‐throughput biomarker discovery and profiling platform which provides an extensive, untargeted, broad metabolite survey of more than 4000 biochemicals.

“This agreement leverages the strengths of our organizations to best serve DHMRI collaborators to understand metabolism and ultimately answer key research questions and deliver healthy food products for consumers. We have worked extensively in food science and nutrition and recognize that our combined resources are indeed complementary. DHMRI is a center of excellence in nutrition research and we are delighted to do our part to meet their growing needs,” says Chris Bernard, senior Vice President of Sales & Marketing for Metabolon.

DHMRI is an established not‐for‐profit research institute that provides flexible, client‐focused research services to academia, government and industry collaborators. This agreement,
consistent with the DHMRI’s collaborative approach to scientific inquiry, provides partners with additional resources for metabolomics. Metabolon’s global metabolomic approach can
pinpoint active pathways which can be further interrogated by targeted and or customized approaches offered by the DHMRI Metabolomics team.

“We are excited to broaden the breadth of services offered by the DHMRI to our collaborators. The benefits stemming from the collective knowledge of our organizations will be readily
realized by researchers, companies and consumers,” said Steve Lommel Ph.D., Interim President, David H. Murdock Research Institute.

Source: David H. Murdock Research Institute

Agilent Technologies Launches New AssayMAP Peptide Sample-Prep Solution

Agilent Technologies Inc. (NYSE: A) recently announced the launch of its new AssayMAP peptide sample-prep solution, which offers automated protein digestion, peptide cleanup and fractionation in preparation for mass-spectrometry analysis.

As more scientists adopt LC/MS analysis for biomarker discovery, the bottleneck shifts to sample preparation. As these types of studies involve much larger numbers of samples, traditional manual methods are proving untenable in terms of hands-on time and unreliable in terms of reproducibility.

“Using the combination of extremely consistent, parallelized digestion with automated reverse-phase cleanup via AssayMAP, at a scale appropriate for ultrasensitive proteomics applications, has enabled us to contemplate collaborative studies of previously unheard-of scales and throughput,” said Jacob Jaffe, Ph.D., assistant director of proteomics platforms at the Broad Institute in Cambridge, Mass.

“The AssayMAP peptide sample-preparation solution is one of the ways Agilent is addressing the need for high-throughput, reproducible sample-preparation methods in front of precision analytical instruments,” said Kathleen Shelton, senior director of automation marketing at Agilent. “Agilent’s unique ability to deliver high-quality solutions for automating sample preparation through analysis enables scientists to maximize workflow productivity and be more successful.”

AssayMAP helps address the bottleneck created with traditional sample preparation for mass-spec analysis and enables unprecedented precision and throughput. This easy-to-use solution includes validated automation protocols driven through intuitive software, the AssayMAP Bravo liquid-handling instrument, and a suite of AssayMAP cartridges optimized for peptide cleanup and fractionation. The AssayMAP peptide sample-prep solution makes large campaigns possible for mass-spec analysis, leveraging the strength of this analytical method to unambiguously identify peptides.

Source: Agilent Technologies

Metabolon and Stemina Biomarker Discovery Settle Patent Dispute

Metabolon, Inc. and Stemina Biomarker Discovery, Inc. have entered into a licensing agreement and dismissed the patent litigation which was pending in the United States District Court, Western District of Wisconsin. Terms of the licensing agreement have not been released.

Elizabeth Donley, Chief Executive Officer of Stemina, said “We are happy to have reached an agreement with Metabolon and to have settled our differences in a way that allows both companies to move forward.” Donley stated she is focused on ongoing autism studies and raising money to accelerate the pace to market for Stemina’s blood test for autism as well as putting the final details together on a large contract with the United States Environmental Protection Agency.

“We are pleased to reach an agreement that brings our pending litigation to an end and further underscores the significant value of Metabolon’s technological innovations and Intellectual Property,” said John Ryals, CEO and President of Metabolon. Ryals continued, “Our focus continues to be the needs of our collaborators and the advancement of the metabolomics science for biomarker discovery, to uncover solutions in medical and nutritional research and the life sciences.”

Source: Business Wire

Fluidigm and Olink Bioscience Bring a New Level of Protein Biomarker Discovery to the Life Science Research Market

Fluidigm and Olink Bioscience have teamed up to enable interrogation of 96 samples across 92 proteins in a single run from one microliter of sample in less than a day.

The two companies will co-market the combination of their respective products — Fluidigm’s BioMarkTM HD System and Olink Bioscience’s Proseek® Multiplex technology — bringing protein research to the Fluidigm platform and Olink Bioscience’s protein detection assays to the high-throughput, high reproducibility and unparalleled sensitivity realm of Fluidigm’s real-time PCR system.

Fluidigm’s BioMark HD System and Olink Bioscience’s Proseek Multiplex technologies provide researchers with the highest throughput multiplexing solution for protein biomarker discovery in the market today. Typically, researchers are limited to working with a few tens-of-protein biomarkers at a time. Using the BioMark HD System with the Proseek Multiplex Oncology I 96×96 Kit, a researcher can simultaneously analyze 96 human samples against a panel of 92 analytes, such as growth factors, inflammatory markers, soluble receptors, or cancer antigens. With the addition of four control analytes (two incubation controls, and extension and detection controls), researchers can now obtain results for up to 9,216 reactions in just a few hours.

The first 92-plex Olink panel, available now, is focused on biomarker discovery for cancer. Panels addressing cardiovascular disease and inflammation are expected to be offered later this year.

“Protein research is so important because these biomarkers are used to monitor health states and predict treatment outcomes in patients. One of the biggest trends in the life sciences industry today is research to uncover biomarkers that can lead to companion diagnostics,” said Simon Fredriksson, Olink Bioscience president and chief executive officer. “Conventional immunoassays have been unable to scale due to increasing antibody cross-reactivity when more and more assays are run simultaneously. Olink’s Proseek Multiplex generates high quality data even in highly multiplexed formats, and using these assays in conjunction with Fluidigm’s BioMark HD System gives protein researchers easy access to unprecedented volume and quality of data.”

The Olink Bioscience assay provides a signal when pairs of antibodies equipped with DNA reporter molecules bind to their targets to create new DNA amplicons. The amplicons are subsequently quantified by high throughput real-time PCR. With PCR’s large dynamic range and superb sensitivity, in combination with Olink Bioscience’s unique protein detection assays, the opportunities are enormous for powerful analysis of multivariate biomarker patterns.

“Analyzing 92 proteins from one microliter of sample enables new biomarker discovery and validation,” said Gajus Worthington, Fluidigm president and chief executive officer. “Many sample sources, including those from biorepositories or model organisms, are limited, and researchers can simply run out before they are able to find useful biomarker panels. The combination of Fluidigm’s BioMark HD System and Olink’s Proseek Multiplex assay represents a robust new tool for the protein research community.”

Fluidigm’s BioMark HD System is a multi-application genomics and proteomics platform that provides results equivalent to the gold standards for every respective experimental approach. The system produces high-quality data from RNA, miRNA and DNA from sample sizes down to the single cell level — and now extends to proteins. The BioMark HD System performs analysis of protein expression, gene expression, copy number variation, SNP genotyping, and digital PCR.

Olink Bioscience’s Proseek Multiplex is a multivariate protein biomarker detection kit based on Olink’s proprietary Proximity Extension Assay (PEA). It uniquely allows multiplexing of immunoassays without compromising assay performance. PEA uses pairs of oligonucleotide-labeled antibodies equipped with DNA reporter molecules to bind to proteins of interest in a highly specific manner, solving the antibody cross-reactivity dilemma that plagues and limits conventional protein assays.

Source: Business Wire

Mount Sinai and Exosome Diagnostics Partner to Accelerate Translation of Body Fluid Molecular Diagnostics to Overcome Limitations of Tissue Biopsy in Areas of Critical Unmet Medical Needs

The Icahn School of Medicine at Mount Sinai and Exosome Diagnostics today announced a collaboration on the research and development of real-time nucleic acid-based body-fluid diagnostics to advance personalized medicine. Exosome will provide technical and development support to Mount Sinai researchers along with early access to proprietary technology products upgrades. The agreement will allow Exosome and Mount Sinai to establish targeted research and biomarker discovery programs in oncology, inflammation and other disease areas. Exosome anticipates pursuing commercial development and FDA review of successful validations for in vitro diagnostics.

“This collaboration represents the model that research centers and private companies need to adopt in the post-recession, sequestered economy to develop diagnostic products that can improve clinical outcomes, help advance drug development programs and help lower healthcare costs,” said James McCullough, Chief Executive Officer of Exosome Diagnostics. “New York State has taken an aggressive and appropriate approach to promoting cooperation of its leading research centers, such as Mount Sinai, with private industry resources and commercial capability to drive translational medicine. Mount Sinai and Exosome together can accelerate cutting-edge diagnostic products to serve the clinical market.”

Carlos Cordon-Cardo, MD, PhD, Chair, Department of Pathology, Icahn School of Medicine at Mount Sinai, added, “As we advance our precise medicine program in the Departments of Pathology and Genomics at Mount Sinai, biofluid-based, point-in-time analyses, made possible by the Exosome Diagnostics-Mount Sinai relationship, will undoubtedly lead to an improved, patient-centric understanding of disease, thereby guiding more informed treatment decisions and response to therapy.”

The agreement was negotiated by Mount Sinai Innovation Partners (Mount Sinai IP), which encourages the commercialization of novel research conducted at the Icahn School of Medicine at Mount Sinai. Mount Sinai plans to leverage the considerable expertise of its clinical investigators in areas of key unmet medical needs to develop clinical study programs taking advantage of Exosome’s unique technology that has the ability to extract high-quality RNA from blood, urine and cerebrospinal fluid.

Under the agreement, Mount Sinai will retain rights to molecular biomarkers associated with disease progression and drug response, and Exosome will retain commercial development rights for molecular in vitro diagnostic products. The collaboration will extend for five years. Dr. Cordon-Cardo receives financial compensation from Exosome Diagnostics as a member of its scientific advisory board.

Source: PR Newswire